Ensysce Biosciences
Ensysce Biosciences's Overview
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing innovative solutions for severe pain and attention deficit hyperactivity disorder (ADHD). The company leverages its Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™) platforms to create next-generation prescription drugs designed to minimize the risk of abuse, misuse, and overdose. Their lead candidates include PF614, a bio-activated extended-release opioid prodrug for chronic pain, and PF614-MPAR, designed to prevent overdose. Ensysce aims to provide safer alternatives to currently available treatments, addressing critical unmet needs in pain management and CNS disorders.
Where is Ensysce Biosciences's Headquarters?
HQ Function
Serves as the primary corporate office, overseeing research and development strategy, clinical trial management, regulatory affairs, and administrative functions.
Notable Features:
Located in a prominent biotech hub, providing access to scientific talent and research collaborations. Office and laboratory spaces designed to support pharmaceutical development.
Work Culture:
A dynamic and innovative environment focused on scientific excellence, collaboration, and a mission-driven approach to developing safer medicines. Emphasis on problem-solving and advancing patient care.
HQ Significance:
Strategically positioned in La Jolla, a well-known center for biomedical research and pharmaceutical development, facilitating access to resources, partnerships, and a skilled workforce.
Values Reflected in HQ: Innovation in drug delivery technology, commitment to addressing the societal impact of prescription drug abuse, and scientific rigor in clinical development processes.
Location:
Ensysce Biosciences is primarily focused on research and development activities within the United States. While its current clinical trials are predominantly US-based, the company's drug candidates have the potential for global impact. Ensysce may pursue international partnerships for later-stage development, regulatory approvals, and commercialization in key markets worldwide as its products mature.
Street Address:
7946 Ivanhoe Avenue, Suite 201
City:
La Jolla
State/Province:
CA
Country:
USA
Ensysce Biosciences's Global Presence
Buying Intent Signals for Ensysce Biosciences
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Ensysce Biosciences
As of April 2025, Ensysce Biosciences' leadership includes:
Investors of Ensysce Biosciences
Ensysce Biosciences has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
During the last 12 months (May 2023 - May 2024), Ensysce Biosciences' C-suite executive team has remained stable, with no new appointments or departures publicly announced for key officer positions. The leadership team has continued in their roles, focusing on advancing the company's clinical programs.
Technology (Tech Stack) used by Ensysce Biosciences
Discover the tools Ensysce Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ensysce Biosciences Email Formats and Examples
Ensysce Biosciences likely utilizes a common professional email format for its employees. Based on industry patterns, a frequently used structure is the first initial of the employee's name followed by their last name.
[first_initial][last]@ensysce.com
Format
lkirkpatrick@ensysce.com
Example
85%
Success rate
News and media
GlobeNewswire • May 8, 2024
Ensysce Biosciences Announces Publication Highlighting the Potential of Nafamostat Mesylate for Protection Against Drug Overdose
Ensysce Biosciences announced a new publication in the 'Journal of Pharmacology and Experimental Therapeutics' detailing the overdose protection potential of nafamostat mesylate when co-administered with opioids. The study suggests nafamostat can prevent respiratory depression, a primary cause of opioid overdose deaths, offering a promising safety net for their TAAP/MPAR drug platforms....more
GlobeNewswire • April 2, 2024
Ensysce Biosciences Announces Successful End-of-Phase-2 Meeting with FDA for Lead Pain Candidate PF614
Ensysce Biosciences reported a successful End-of-Phase-2 (EOP2) meeting with the U.S. FDA for PF614, its lead Trypsin-Activated Abuse Protection (TAAP™) opioid prodrug for chronic pain. The company received clear guidance for its Phase 3 program, marking a significant step towards potential approval....more
GlobeNewswire • March 12, 2024
Ensysce Biosciences Announces Presentations at Upcoming March Scientific and Investor Conferences
Ensysce Biosciences announced its participation and presentations at several key scientific and investor conferences in March 2024, including the 36th Annual ROTH Conference and the BIO-Europe Spring conference, to discuss its drug development programs and corporate progress....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Ensysce Biosciences, are just a search away.